2 not yet recruiting, 1 recruiting, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 1, Unknown 1 |
Follow Li Zhiming: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone - DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Not yet recruiting | Li Zhiming | 40 | 2026-01-15 | 2025-11-19 |
| Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL ZCR-CHOP, R-CHOP - BTK Inhibitors, Histone Deacetylase Inhibitor | Phase 2 | Not yet recruiting | Li Zhiming | 128 | 2025-06-01 | 2025-03-24 |
| Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL ZO - Initial MZL, Untreated MZL | Phase 2 | Recruiting | Li Zhiming | 33 | 2024-11-13 | 2025-05-22 |
| Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma Selinexor, Rituximab, Cyclophosphamide - DLBCL Germinal Center B-Cell Type | Phase 2 | Unknown | Li Zhiming | 50 | 2022-07-26 | 2024-06-17 |
Dendritic Cell Sarcoma, Interdigitating (1)
Cyclophosphamide (2) · Doxorubicin (2) · Prednisone (2) · R-CHOP protocol (1) · Rituximab (1) · Vincristine (1) · glofitamab (1) · polatuzumab vedotin (1) · selinexor (1)
China (4)
Zhiming Li, M.D. (1) · Zhiming Li, Ph.D (1) · Zhiming Li, Professor (1)